---
title: "Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: medical information"
description: "Questions on Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Indication, Clinical trials, Safety, and Dosing and administration. 12 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: medical information

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

Questions that apply to every indication of Vabysmo are on [Vabysmo (faricimab-svoa), all indications](https://www.evicenter.com/medical-information/vabysmo).

## [Indication](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication)

- [Is Vabysmo approved for wet AMD?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication#vabysmo-namd-indication)

## [Clinical trials](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials)

- [How were the Vabysmo wet AMD trials (TENAYA and LUCERNE) designed?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials#vabysmo-tenaya-lucerne-design)
- [How well does Vabysmo work vs aflibercept for wet AMD (TENAYA, LUCERNE)?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials#vabysmo-namd-vision-vs-aflibercept)
- [Were Vabysmo wet AMD results consistent across age, sex, race, and baseline vision?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials#vabysmo-namd-subgroups)
- [How many wet AMD patients were on Vabysmo every 16 weeks at week 48?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials#vabysmo-namd-dosing-interval-results)
- [Does Vabysmo reduce retinal thickness (CST) in wet AMD trials?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials#vabysmo-namd-retinal-thickness)

## [Safety](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety)

- [What side effects did Vabysmo cause in wet AMD trials?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety#vabysmo-namd-side-effects)
- [How common are cataracts with Vabysmo in wet AMD trials?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety#vabysmo-cataract)
- [Can Vabysmo cause retinal pigment epithelial tears in wet AMD?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety#vabysmo-rpe-tear)
- [How common is eye inflammation with Vabysmo in wet AMD trials?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety#vabysmo-intraocular-inflammation)
- [Does Vabysmo raise stroke or heart attack risk in wet AMD?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety#vabysmo-namd-stroke-heart-attack)

## [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration)

- [What is the Vabysmo dosing schedule for wet AMD?](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration#vabysmo-namd-dosing)
